Johnson & Johnson‘s (NYSE:JNJ) LifeScan arm said it plans to conduct a 142-person clinical trial to see whether 1 of its OneTouch blood glucose meters works better for patients with a companion app or on its own.
Researchers are slated to look at patients using LifeScan’s OneTouch Verio Flex blood glucose meter along with the OneTouch Reveal app, versus patients only using the Verio Flex over 6 months.
The randomized trial will see which group of patients with Type I and Type II diabetes has better blood sugar levels. The study will also attempt to measure which option leads to better patient satisfaction, according to details of the trial posted on ClinicalTrials.gov.
Recruitment hasn’t begun yet, but plans are to complete the study by May 2016.
LifeScan gained the FDA’s O.K. in March 2013 for OneTouch Reveal, which is available on iPhone, iPad, or iPod touch. The Verio blood glucose monitor, used with the app, allows blood glucose levels to be sent automatically to mobile devices, giving patients a 14-day summary in an easy-to-understand visual. Patients can then share that information with doctors or friends via text or email.